Want to see HK:2500 full AI Analyst Report?
Top Page
Venus Medtech (Hangzhou), Inc. Class H
(2500)
Select Model
Select Model
Rating:45Neutral
Price Target:
HK$1.00
▼(-59.35% Downside)
Action:Reiterated
Date:07/22/26
The score is primarily constrained by weak financial performance (persistent losses, a sharp revenue decline, and continued cash burn) and a bearish technical setup (price below key moving averages with negative MACD). Improving leverage on the balance sheet provides some stability, but valuation is difficult to support given negative earnings and no provided dividend yield.
Positive Factors
Focused Structural Heart Platform
Specialization in structural heart interventions gives Venus Medtech a focused position in a clinically important device category, while transcatheter and minimally invasive offerings create a coherent platform for potential product expansion over the medium term.
Negative Factors
Sharp Revenue Decline
A sharp revenue contraction weakens the scale benefits required for a specialized medical-device developer and may reduce resources available for commercialization and innovation. Continued softness would make it harder to absorb fixed costs and establish a durable growth trajectory.
Read all positive and negative factors
Positive Factors
Negative Factors
Focused Structural Heart Platform
Specialization in structural heart interventions gives Venus Medtech a focused position in a clinically important device category, while transcatheter and minimally invasive offerings create a coherent platform for potential product expansion over the medium term.
Read all positive factors
Venus Medtech (Hangzhou), Inc. Class H (2500) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$518.19M
Dividend YieldN/A
Average Volume (3M)826.95K
Price to Earnings (P/E)―
Beta (1Y)0.52
Revenue Growth-38.15%
EPS Growth25.70%
CountryHK
Employees557
SectorHealthcare
Sector Strength45
IndustryMedical - Specialties
Share Statistics
EPS (TTM)-1.06
Shares Outstanding441,010,220
10 Day Avg. Volume318,850
30 Day Avg. Volume826,954
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)0.53
Price to Sales (P/S)3.05
P/FCF Ratio-2.82
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.25
Revenue Forecast (FY)HK$791.75M
Venus Medtech (Hangzhou), Inc. Class H Business Overview & Revenue Model
Company Description
Venus Medtech (Hangzhou) Inc., together with its subsidiaries, engages in the research, development, manufacturing, and sale of bioprosthetic heart valves in Mainland China and internationally. The company’s offers transcatheter aortic heart valve...
How the Company Makes Money
The company primarily makes money by selling structural heart interventional medical devices to hospitals and healthcare providers, generating revenue from product sales associated with transcatheter valve procedures and related accessories/consum...
Venus Medtech (Hangzhou), Inc. Class H Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
63
Positive
Cash Flow
24
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 255.30M | 306.79M | 470.83M | 491.37M | 406.46M | 415.86M |
| Gross Profit | 135.57M | 211.83M | 367.75M | 389.20M | 314.00M | 324.34M |
| EBITDA | -250.75M | -247.99M | -612.96M | -547.84M | -999.37M | -324.03M |
| Net Income | -464.44M | -407.69M | -714.31M | -703.75M | -1.06B | -373.64M |
Balance Sheet | ||||||
| Total Assets | 2.22B | 2.52B | 3.25B | 4.41B | 5.28B | 5.11B |
| Cash, Cash Equivalents and Short-Term Investments | 88.20M | 280.52M | 305.70M | 781.64M | 1.88B | 2.96B |
| Total Debt | 202.65M | 216.43M | 369.09M | 826.19M | 899.64M | 70.78M |
| Total Liabilities | 697.43M | 757.14M | 1.04B | 1.49B | 1.65B | 477.61M |
| Stockholders Equity | 1.53B | 1.76B | 2.21B | 2.92B | 3.61B | 4.55B |
Cash Flow | ||||||
| Free Cash Flow | -386.81M | -332.12M | -17.82M | -872.93M | -908.23M | -602.08M |
| Operating Cash Flow | -381.81M | -321.35M | 23.74M | -610.02M | -729.46M | -456.92M |
| Investing Cash Flow | 469.88M | 364.06M | -19.90M | -346.86M | -1.07B | -653.04M |
| Financing Cash Flow | -294.73M | -184.05M | -487.34M | -173.99M | 635.14M | 1.39B |
Venus Medtech (Hangzhou), Inc. Class H Technical Analysis
Negative
2.46
Price Trends
1.11
Positive
1.21
Negative
1.81
Negative
Market Momentum
0.01
Positive
47.79
Neutral
24.47
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2500, the sentiment is Negative. The current price of 2.46 is above the 20-day moving average (MA) of 1.17, above the 50-day MA of 1.11, and above the 200-day MA of 1.81, indicating a neutral trend. The MACD of 0.01 indicates Positive momentum. The RSI at 47.79 is Neutral, neither overbought nor oversold. The STOCH value of 24.47 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2500.
Venus Medtech (Hangzhou), Inc. Class H Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | HK$2.33B | 21.47 | 7.90% | ― | 59.30% | 131.03% | |
59 Neutral | HK$2.92B | 29.09 | 4.08% | ― | 94.80% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | HK$1.63B | -0.86 | -6.69% | ― | ― | ― | |
46 Neutral | HK$11.65B | 31.22 | 6.07% | 0.06% | -3.62% | ― | |
45 Neutral | HK$518.19M | -0.92 | -28.24% | ― | -38.15% | 25.70% | |
39 Underperform | HK$21.97B | -75.36 | -52.78% | ― | 114.97% | 63.21% |
* Healthcare Sector Average
HK:2500
Venus Medtech (Hangzhou), Inc. Class H
1.14
-2.08
-64.60%
HK:0853
MicroPort Scientific
6.08
-8.75
-59.01%
HK:2160
MicroPort CardioFlow Medtech Corp.
1.28
-5.97
-82.34%
HK:2235
MicroTech Medical (Hangzhou) Co., Ltd. Class H
6.99
-1.05
-13.06%
HK:2252
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H
21.18
-9.48
-30.92%
HK:6609
Shanghai Heartcare Medical Technology Corp. Ltd. Class H
58.40
-6.60
-10.15%
Venus Medtech (Hangzhou), Inc. Class H Corporate Events
Venus Medtech Calls EGM to Approve Share and Bond Subscription Plan
Sep 14, 2026
Venus Medtech (Hangzhou) Inc. has called an extraordinary general meeting in Hangzhou on September 30, 2026, to seek shareholder approval for a subscription of new shares and convertible bonds under a subscription agreement. The company also plans...
Venus Medtech Sets Extraordinary General Meeting for New Share and Bond Subscription
Sep 11, 2026
Venus Medtech (Hangzhou), Inc., a Hong Kong-listed Chinese medical technology company specializing in cardiovascular devices, maintains a diversified shareholder base across H shares and unlisted foreign shares. The firm is governed by a board tha...
Venus Medtech Plans Major Share and Convertible Bond Subscription
Sep 10, 2026
Venus Medtech (Hangzhou) Inc. has entered into a Subscription Agreement with an independent investor for a substantial capital injection via new shares and convertible bonds. The deal underscores the company’s continued effort to strengthen ...
Venus Medtech Interim Loss Widens as Revenue and Margins Decline
Aug 31, 2026
Venus Medtech (Hangzhou) Inc. reported a sharp deterioration in interim results for the six months ended June 30, 2026, as revenue fell 27.6% year on year to RMB135.5 million while gross profit dropped 32.2% to RMB93.5 million. The company’s...
Venus Medtech Schedules Board Meeting to Approve 2026 Interim Results
Aug 19, 2026
Venus Medtech (Hangzhou) Inc., a Hong Kong-listed medical technology company incorporated in the People’s Republic of China, is governed by a mixed board of executive, non-executive and independent non-executive directors, led by Executive D...
Venus Medtech Subscription Deal Lapses as Company Pursues New Financing Plan
Jul 5, 2026
Venus Medtech (Hangzhou) Inc. announced that its subscription agreement for a proposed issue of up to RMB200 million in convertible bonds has lapsed after certain conditions precedent were not met by the agreed long stop date, releasing both parti...
Venus Medtech Explores Up to RMB500 Million Investment via Shares and Convertible Bonds
Jul 1, 2026
Venus Medtech (Hangzhou) Inc. has signed a non-binding investment term sheet with Hangzhou Hi-Tech, Hangzhou Yingzhiqin and other potential investors for a prospective capital injection of up to RMB500 million. The funding would be raised through ...
Venus Medtech Wins Shareholder Backing for All 2025 AGM Resolutions
Jun 25, 2026
Venus Medtech (Hangzhou) Inc. reported that all resolutions tabled at its 2025 annual general meeting in Hangzhou were approved by shareholders, with participation representing 24.02% of the issued share capital. The meeting, chaired by board chai...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.